DDInter1736 DDInter1376
Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy.[L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibitors like [sildenafil], tadalafil has greater selectivity for PDE5 and a longer half-life which has made it a more suitable option for chronic once-daily dosing in the treatment of PAH.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Tadalafil {u} (Compound) binds {v} (Gene) PDE11A
Tadalafil {u} (Compound) palliates {v} (Disease) systemic scleroderma
Tadalafil {u} (Compound) causes {v} (Side Effect) Conjunctivitis
Tadalafil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Minoxidil
Tadalafil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Epoprostenol
Tadalafil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Tadalafil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Imatinib
Tadalafil {u} may lead to a major life threatening interaction when taken with {v} Amyl Nitrite
Tadalafil (Compound) binds PDE11A (Gene)
Tadalafil (Compound) palliates systemic scleroderma (Disease)
Tadalafil (Compound) causes Conjunctivitis (Side Effect)
Tadalafil may cause a minor interaction that can limit clinical effects when taken with Minoxidil
Tadalafil may cause a minor interaction that can limit clinical effects when taken with Epoprostenol
Tadalafil may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Tadalafil may cause a moderate interaction that could exacerbate diseases when taken with Imatinib
Tadalafil may lead to a major life threatening interaction when taken with Amyl Nitrite